Drug Profile
Berdazimer sodium - SB 208 - Novan Inc
Alternative Names: MAP3-NONOate - SB-208; NVN1000-SB208; SB-208Latest Information Update: 18 Feb 2022
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Novan Inc
- Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Free radicals; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Onychomycosis; Tinea pedis
Most Recent Events
- 18 Feb 2022 Berdazimer sodium SB 208 is still in phase II trials for Tinea pedis in Dominican Republic (Novan pipeline, February 2022)
- 17 May 2021 Berdazimer sodium - SB 208 is available for licensing as of 31 Dec 2020. https://novan.com/contact/
- 28 Apr 2021 No recent reports of development identified for phase-I development in Onychomycosis in USA (Topical, Gel)